MENU

CLDX Celldex Therapeutics Forecast, Technical & Fundamental Analysis

a developer of immunotherapy technologies for the treatment of cancer and other diseases

Industry Biotechnology
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CLDX is expected to report earnings to rise 8.14% to -69 cents per share on March 03

Celldex Therapeutics CLDX Stock Earnings Reports
Q4'24
Est.
$-0.69
Q3'24
Beat
by $0.03
Q2'24
Beat
by $0.05
Q1'24
Beat
by $0.15
Q4'23
Missed
by $0.07
The last earnings report on November 06 showed earnings per share of -63 cents, beating the estimate of -67 cents. With 284.56K shares outstanding, the current market capitalization sits at 1.73B.
A.I. Advisor
published General Information

General Information

a developer of immunotherapy technologies for the treatment of cancer and other diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
53 Frontage Road
Phone
+1 908 200-7500
Employees
160
Web
https://www.celldex.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

CLDX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with KRYS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-0.61%
KRYS - CLDX
56%
Loosely correlated
+0.85%
ALT - CLDX
45%
Loosely correlated
-6.67%
BEAM - CLDX
43%
Loosely correlated
-1.21%
NTLA - CLDX
42%
Loosely correlated
-1.87%
EDIT - CLDX
40%
Loosely correlated
+2.70%
More